Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
Stopped Enrollment discontinued following DMC recommendation based on futility with regards to primary endpoint
Conditions
Interventions
- DRUG: RMC-035
- DRUG: Placebo
Sponsor
Guard Therapeutics AB